OrbiMed’s Forte Biosciences FBRX Stock Holding History

OrbiMed’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$31M	Hold	1,196,955	–	–	0.61%	47
2025 Q4	$32.6M	Hold	1,196,955	–	–	0.67%	45
2025 Q3	$18M	Hold	1,196,955	–	–	0.42%	56
2025 Q2	$15.5M	Buy	1,196,955 +603,867	+102%	+$5.2M	0.39%	49
2025 Q1	$4.6M	Sell	593,088 -6,912	-1%	-$81.6K	0.11%	79
2024 Q4	$13.6M	Buy	+600,000	New	+$7.14M	0.28%	65
2021 Q2	–	Sell	-6,387	Closed	-$5.47M	–	165
2021 Q1	$5.47M	Buy	6,387 +2,699	+73%	+$2.21M	0.05%	140
2020 Q4	$3.36M	Sell	3,688 -9,931	-73%	-$9.34M	0.03%	142
2020 Q3	$16.5M	Sell	13,619 -24,394	-64%	-$16.2M	0.21%	94
2020 Q2	$13.9M	Buy	+38,013	New	+$17M	0.2%	88

Other funds holding FBRX

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed's FBRX Position: Q1 2026 in Review

OrbiMed held its Forte Biosciences (FBRX) position steady in Q1 2026 at 1,196,955 shares worth $31M. The position accounts for 0.61% of the portfolio, ranked #47.

OrbiMed first reported a position in FBRX in Q2 2020 and has held it in 10 quarters since. The position peaked at $32.6M in Q4 2025. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

OrbiMed held 1,196,955 shares of Forte Biosciences worth $31M as of Q1 2026.
OrbiMed left its Forte Biosciences share count unchanged in Q1 2026.
Forte Biosciences made up 0.61% of OrbiMed's portfolio in Q1 2026, its #47 holding.
OrbiMed first reported a position in Forte Biosciences in Q2 2020 and has held it in 10 quarters since.
OrbiMed's Forte Biosciences position peaked at $32.6M in Q4 2025.
68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.